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Abstract
Background: MR CLEAN was the first randomized trial to demonstrate the short-term clinical effectiveness of
endovascular treatment in patients with acute ischemic stroke caused by large vessel occlusion in the anterior
circulation. Several other trials confirmed that endovascular treatment improves clinical outcome at three months.
However, limited data are available on long-term clinical outcome. We aimed to estimate the effect of endovascular
treatment on functional outcome at two-year follow-up in patients with acute ischemic stroke. Secondly, we aimed to
assess the effect of endovascular treatment on major vascular events and mortality during two years of follow-up.
Methods: MR CLEAN is a multicenter clinical trial with randomized treatment allocation, open-label treatment, and
blinded endpoint evaluation. Patients included were 18 years or older with acute ischemic stroke caused by a proven
anterior proximal artery occlusion who could be treated within six hours after stroke onset. The intervention contrast
was endovascular treatment and usual care versus no endovascular treatment and usual care. The current study
extended the follow-up duration from three months to two years.
The primary outcome is the score on the modified Rankin scale at two years. Secondary outcomes include all-cause
mortality and the occurrence of major vascular events within two years of follow-up.
Discussion: The results of our study provide information on the long-term clinical effectiveness of endovascular
treatment, which may have implications for individual treatment decisions and estimates of cost-effectiveness.
Trial registration: NTR1804. Registered on 7 May 2009; ISRCTN10888758. Registered on 24 July 2012 (main MR CLEAN
trial); NTR5073. Registered on 26 February 2015 (extended follow-up study).
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Introduction
Stroke is one of the leading causes of disability and death
worldwide [1]. Until recently the only proven effective
therapy for acute ischemic stroke was intravenous (IV)
thrombolysis with recombinant tissue plasminogen ac-
tivator (rt-PA) [2]. In January 2015 the results of the
Multicenter Randomized Clinical Trial of Endovascular
Treatment for Acute Ischemic Stroke in the Netherlands
(MR CLEAN) were published and demonstrated the clin-
ical effectiveness of endovascular treatment with respect
to functional recovery at three months [3]. In the subse-
quent months several other trials confirmed these results
[4–8]. However, results on long-term clinical outcome are
still lacking. In the current paper we present the design
and statistical analysis plan (SAP) of the extended, two-
year clinical follow-up study of the MR CLEAN trial. The
primary objective of our study is to estimate the effect of
endovascular treatment in comparison to standard treat-
ment on functional outcome at two-year follow-up in
patients with acute ischemic stroke caused by a proximal
occlusion in the anterior cerebral circulation. Secondary
objectives include the effect of endovascular treatment on
major vascular events, mortality, and quality of life during
two years of follow-up.
Methods
Study design and overall study plan
MR CLEAN was a multicenter clinical trial with random-
ized treatment allocation, open-label treatment, and blinded
endpoint evaluation. The intervention contrast was endo-
vascular treatment (mechanical thrombectomy with stent
retriever in 97% of patients) versus no endovascular treat-
ment. The treatment was provided in addition to usual
care, which included intravenously administered rt-PA (in
approximately 90% of patients). Patients were randomized
in a 1:1 ratio. The randomization procedure was web-
based, with the use of permuted blocks, stratified by center,
with dichotomized score on the National Institutes of
Health Stroke Scale (NIHSS), treatment with intravenously
administered rt-PA, and intended mechanical treatment
[9]. Data were collected at baseline, 24 hours, one week,
and three months for the main trial. Detailed information
on the main trial, treatment, blinding, statistical analysis,
and determination of sample size is given in the protocol
and SAP of the MR CLEAN trial [10].
Because of funding issues, the extended follow-up study
came into effect only in May 2013. At that moment the
inclusion of the MR CLEAN trial was well halfway of the
projected 500 patients to be included. As a result, many
patients had already completed their three-month follow-
up, and some patients had even passed the two-year
follow-up point. After checking the Dutch Death Certifi-
cate Register, surviving patients were re-invited to take
part in the extended follow-up study. If patients did not
wish to participate, a reply was to be sent back to the trial
office. Approximately two weeks after sending the invita-
tion letter, all willing participants were contacted by tele-
phone to confirm their participation and to explain
additional study goals and activities. For the remaining
MR CLEAN trial inclusions and their legal representa-
tives, the new follow-up duration including additional
study activities was explained in an adjusted MR CLEAN
informed consent letter. All participating patients or their
primary caregivers, for patients who were unable to
respond, were contacted by telephone at six months, one
year, 18 months and two years of follow-up. One experi-
enced research nurse, blinded for treatment allocation,
assessed functional outcome using the modified Rankin
scale (mRS) and noted the occurrence of medical events
in between follow-ups by a telephone interview [11]. The
patient or his/her primary caregiver was also invited to
complete the EuroQol EQ-5D-3L questionnaire to assess
quality of life [12].
Study population
Patients aged 18 years or older with acute ischemic stroke
caused by an anterior proximal artery occlusion who were
able to be treated within six hours after stroke onset were
eligible for inclusion in MR CLEAN. Detailed inclusion
and exclusion criteria are described in the protocol of the
MR CLEAN trial [10].
Because the current extended follow-up study started
more than two years later than the main MR CLEAN
trial, many patients had already completed their partici-
pation in the main trial at the start of the extended
follow-up study. As a result different groups of patients
emerge:
1. Patients randomized before May 2011 (group 1)
2. Patients randomized between May 2011 and May
2013 who:
(a).Had died by May 2013 (group 2)
(b).Were untraceable or were living abroad in May
2013 (group 3)
(c).Did not provide consent for extended follow-up
or who withdrew consent during follow-up
(group 4)
(d).Provided consent for extended follow-up study with
subsequently a different number of measurements
during follow-up (group 5)
3. Patients randomized after May 2013 (group 6).
As a consequence of the above, the population for the
two-year follow-up analysis will be somewhat smaller
than the one for the three-month follow-up analysis,
with a varying number of available measurements over
time. All patients with an available two-year follow-up
visit will be included in the main long-term follow-up
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analyses. These include patients from group 2, group 5 and
group 6. One major concern regarding the estimation of
treatment effect in this selected patient population might
be an unbalanced distribution in treatment arms at two
years. A possible threat for the treatment effect estimation
at two years could be bias created by patients who decided
not to consent for the long-term follow-up study (group
4). One reason for not participating in the long-term
follow-up study might be that these patients had worse
outcomes after three months and therefore felt they were
not capable of participating in the follow-up visits. They
may also be dissatisfied with being allocated to standard
treatment as a reason for refusal for further participation.
Both motivations may lead to relatively more patients
available for the long-term follow-up who received inter-
vention and had a good outcome at three months. This
may cause serious selection bias, resulting in overesti-
mation of the treatment effect.
To assess whether indeed the patient selection resulted
in an unbalanced distribution, and thus an unrepresenta-
tive two-year trial population, we will compare main prog-
nostic variables, three-month functional outcome, and
treatment allocation between patients who did not
consent (group 4) to patients who consented for the
extended follow-up study (groups 5 and 6) and perform
additional sensitivity analyses [13–15]. In addition we will
compare treatment effect on functional outcome at three
months in patients who did not consent for the extended
follow-up to patients with available two-year follow-up.
Subgroup populations
The effect of intervention on the main endpoint, the
mRS score at two years of follow-up, will be analyzed in
the same predefined subgroups as in the main trial,
including the following:
 Age 80 or older at time of randomization versus age
younger than 80 at time of randomization
 NIHSS at randomization in tertiles (2–15, 16–19,
and 20 or higher)
 Terminal internal carotid artery occlusion present
versus no terminal internal carotid artery occlusion
 Time since stroke onset to randomization
120 minutes or less versus more than 120 minutes
 Extracranial >50% carotid stenosis or occlusion
versus no >50% carotid stenosis or occlusion
 Alberta Stroke Program Early Computed
Tomography Score (ASPECTS) 0–4, 5–7, 8–10
Study endpoints
Primary outcome measure
The primary outcome is the clinical outcome on the
mRS at two years. The mRS is an ordinal scale ranging
from 0 (no disability) to 6 (death) [11].
Secondary outcome measures
Secondary outcome measures include:
 All-cause mortality within two years of follow-up. In
addition, we will assess mortality in the period between
three months and two years after inclusion in patients
who were alive at three months of follow-up.
 Improvement according to the classical
dichotomizations of the mRS at two years including
mRS 0–1 (excellent outcome) versus 2–6; mRS 0–2
(independency) versus 3–6, and mRS 0–3 (moderate
good outcome) versus 4–6.
 First new major vascular events between three
months and two years of follow-up.
 The quality of life using the EuroQol EQ-5D-3L
questionnaire.
Definitions and assessment of major vascular events
Definition of major vascular event Major vascular
events include fatal or nonfatal cardiac events, fatal or
nonfatal stroke, or fatal or nonfatal major peripheral arter-
ial or thrombo-embolic events. Cardiac events include
myocardial infarction, resuscitation after cardiac arrest,
and hospitalization for unstable angina or cardiac insuffi-
ciency. Major peripheral events include all events related
to noncoronary arterial disease leading to hospitalization
or revascularization (e.g., new or worsening of claudica-
tion leading to revascularization). Major thrombo-embolic
events include pulmonary embolism or cerebral venous
thrombosis.
Recurrent stroke was defined according to the World
Health Organization criteria as “rapidly developing
symptoms and/or signs of focal, and at times global, loss
of cerebral function, with symptoms lasting more than
24 hours or leading to death with no apparent cause
other than that of vascular origin” [16]. We defined a re-
current stroke as a stroke, using the above definition, in
which (1) there was clinical evidence of the sudden onset
of a new focal neurological deficit with no apparent
cause other than that of vascular origin (i.e., the deficit
could not be ascribed to an intercurrent acute illness,
epileptic seizure, or toxic effect) occurring at any time
after the index stroke; or (2) there was clinical evidence
of the sudden onset of an exacerbation of a previous
focal neurological deficit with no apparent cause other
than that of vascular origin [17, 18].
Assessment of major vascular events Reported events
were checked by contacting the treating physicians,
hospitals, and/or general practitioners. Events had to be
confirmed by available reports of events or otherwise
orally confirmed by the treating physician or general
practitioner. All events were centrally reviewed by two
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investigators (LAvdB and YBWEMR), who were blinded
for treatment allocation.
Statistical analysis
General considerations
LAvdB, MGWD, and YBWEMR will perform all analyses.
Estimates of treatment effects will be presented with 95%
confidence intervals, unless specified otherwise. A two-
tailed P value of ≤0.05 will be considered significant for all
measures. All analyses will be based on the intention-to-
treat principle. Analyses of the efficacy parameters will be
adjusted according to the SAP of the main trial, and
results of the unadjusted analyses will be provided. The
analysis will be performed after the last randomized
patient has reached the two year follow-up, after all data
have been validated and the database is cleaned and after
approval of the SAP by the executive committee.
As of 30 March 2016, follow-up was completed. The
database for the long-term clinical follow-up was frozen
as of 6 April 2016. The same day the data were extracted
from the online database. On 1 May 2016 the SAP was
finalized and agreed on by the executive committee for
the unblinded analyses of the two-year results by LAvdB,
MGWD, and YBWEMR. Preliminary results were
presented at the 2016 European Stroke Organization
Conference, held on 12 May 2016 in Barcelona, Spain.
Analysis of demographics and baseline characteristics
The baseline characteristics of all subjects listed per
treatment sequence will be outlined in a table and sum-
marized with descriptive statistics.
Analyses of efficacy parameters
Primary endpoint The long-term follow-up data will be
analyzed at two years using the same methods as the
three-month follow-up in MR CLEAN. The primary
effect parameter takes the whole range of the mRS into
account and will be estimated as an odds ratio for
improvement on the mRS by ordinal logistic regression
(shift analysis) [19].
Multivariable regression analysis will be used to ad-
just for chance imbalances in main prognostic variables
between intervention and control group in the primary
effect analysis, but also in all secondary analyses and
subgroup analyses [20]. These main prognostic vari-
ables are age, stroke severity (NIHSS) at baseline, time to
randomization, previous stroke, atrial fibrillation, diabetes
mellitus, and terminal internal carotid artery occlusion
versus no terminal internal carotid artery occlusion.
Secondary endpoints All-cause mortality for both time
periods (inclusion until two years, and between three
months and two years) will be analyzed using the log-
rank test with Kaplan-Meier plots. To adjust for the pre-
specified factors, a Cox regression model will be applied
with a risk ratio expressed as a hazard ratio.
Major vascular events between three months and two
years of follow-up will be analyzed by using person-years
at risk to calculate the event rate in both treatment
arms. This way events reported by patients who were
lost to follow-up during the extended follow-up will be
taken into account. Between-group differences will be
expressed as relative risk reduction.
The dichotomizations of the mRS at two years includ-
ing mRS 0–1 versus 2–6 and mRS 0–2 versus 3–6 will
be estimated with a multiple logistic regression with the
odds ratio as effect parameter.
Quality of life will be displayed graphically per treat-
ment group and for each dimension of the EQ-5D:
mobility, self-care, usual activities, pain/complaints, and
mood (anxiety/depression). Furthermore, a composite
health utility value will be derived for each completed
five-dimensional EQ-5D questionnaire with readily avail-
able scoring algorithms, reflecting societal preferences
for different health states, elicited by time trade-off tech-
niques applied to the general population [21]. The effect
parameter will be a regression parameter beta, estimated
with a multiple linear regression model.
Additional procedures and sensitivity analyses for missing
data
As stated earlier, patients who did not consent to the ex-
tended follow-up may introduce an important selection
bias. To gain as much information as (legally) possible on
the clinical status of these patients, a waiver from the In-
stitutional Review Board was obtained to assess the vital
status of these patients at two years of follow-up. This in-
formation will be used for the survival analysis as well as
for the sensitivity analyses of the primary outcome.
First we will compare patients who did not consent to
patients who consented to the extended follow-up, includ-
ing the following variables: main prognostic variables,
treatment allocation, and functional outcome at three
months (dichotomized mRS 0–3 versus 4–6). To test for
any statistically significant differences between groups,
categorical variables will be compared by the chi-square
test and continuous variables by Student’s t test or, in case
of a non-normal distribution, the Mann-Whitney U test.
Finally, we will develop alternative modeling scenarios to
assess the robustness of the base case results (complete
case analyses) of the primary outcome. Based on clinically
plausible scenarios, the analyses will consist of two differ-
ent scenarios created by single imputation for the mRS at
two years in patients who did not consent:
1. Last observation carried forward: patients of whom
we have information on vital status at two years and
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who died will be scored as an mRS 6 (death), and
for all other patients the mRS score will be imputed
with the available three month mRS score.
2. Worst case scenario: patients of whom we have
information on vital status at two years and who
died will be scored as an mRS 6; for patients with an
mRS score of 5 (=severe disability) at three months,
the mRS score will be imputed with an mRS 5; and
for patients with an mRS <5 at three months, the
mRS score will be imputed with mRS 5.
Finally, we will compare treatment effect on functional
outcome at three months in patients who did not con-
sent to the extended follow-up to patients with available
two-year follow-up.
Subgroup analyses
Subgroups will be analyzed with an interaction term for
each subgroup by treatment allocation and reported as
subgroup-specific estimates with 95% confidence inter-
vals, displayed in a forest plot.
Discussion
The MR CLEAN trial aimed to evaluate the effect of
endovascular treatment on functional outcome after
three months in patients with acute ischemic stroke.
Additionally, it assessed safety and effect on recanaliza-
tion of endovascular therapy. Limited evidence is avail-
able for the long-term outcome after endovascular
treatment for acute ischemic stroke. In the current study
we extend the follow-up duration to two years after
randomization to estimate the effect of endovascular
treatment on functional outcome over the longer term.
Secondary objectives include the effect of endovascular
treatment on major vascular events and mortality during
two years. This paper allows for peer review of the pro-
posed methods and provides a transparent statement of
the planned analyses.
Limitations and concerns
The sample size of the main trial was not powered for an
extended follow-up. During longer term follow-up studies,
loss to follow-up is a well-known phenomenon, resulting
in smaller sample sizes. Furthermore, loss to follow-up
may cause serious attrition bias. Both these problems may
play an important role in our study, mainly because of the
late start of the extended follow-up study. We therefore
will provide clear information on the flow of patients
through the study and differences in baseline and mea-
sured variables according to provision of consent for the
long-term follow-up, and we will perform additional sensi-
tivity analyses for different scenarios.
The results of our study will provide information on the
long-term clinical effectiveness of endovascular treatment
for patients with acute ischemic stroke. The benefit of
endovascular treatment on short-term disability might
translate into longer term improvements in survival
and functional status, which could influence individual
treatment decisions and estimates of cost-effectiveness.
Subsequently, it will have important additional value
concerning implementation of endovascular treatment
all over the world.
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